Alpine Immune Sciences
Immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $4.9b Valuation: $4.9b 83.2x EV/Revenue -156.0x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (59 %) | 147 % | 436 % | 151 % | 28 % | 96 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5127 %) | (2386 %) | (291 %) | (212 %) | (183 %) | (53 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5175 %) | (2405 %) | (299 %) | (215 %) | (192 %) | (55 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4109 % | 2060 % | 291 % | 251 % | 234 % | 137 % | - |
Source: Company filings or news article, Equity research estimates
Related Content
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a clinical-stage biotechnology company based in Seattle, Washington. The company specializes in developing innovative protein-based immunotherapies aimed at treating cancer and autoimmune inflammatory diseases. Immunotherapies are treatments that use certain parts of a person’s immune system to fight diseases such as cancer.
Alpine Immune Sciences leverages its proprietary Variant Immunoglobulin Domain (vIgD) platform, which uses a technique called directed evolution. This process involves creating and selecting proteins with enhanced or new functions, which can potentially modulate the human immune system. Essentially, they develop specialized proteins that can either stimulate or inhibit immune responses, depending on the therapeutic need.
The company's leading product candidates include ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, which is currently in Phase 1 clinical trials for patients with advanced malignancies. This means that ALPN-202 is designed to both activate certain immune cells and block proteins that prevent the immune system from attacking cancer cells, thereby enhancing the body's ability to fight cancer.
Alpine Immune Sciences primarily serves patients with cancer and autoimmune diseases, working within the broader biopharmaceutical market. Their business model focuses on research and development (R&D) to create new therapies, followed by clinical trials to test these therapies' safety and effectiveness. They generate revenue through partnerships and licensing agreements with larger pharmaceutical companies, such as their collaboration with AbbVie for the development and commercialization of ALPN-101.
In summary, Alpine Immune Sciences is at the forefront of developing next-generation immunotherapies, with a strong focus on leveraging advanced protein engineering to create treatments that can significantly impact patients' lives.
Keywords: immunotherapy, cancer treatment, autoimmune diseases, protein engineering, clinical trials, biotechnology, ALPN-202, vIgD platform, directed evolution, biopharmaceutical.
Tech stack
Investments by Alpine Immune Sciences
Edit